Literature DB >> 16205915

A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors.

Katerina Antoniou1, Zeta Papadopoulou-Daifoti, Thomas Hyphantis, Georgia Papathanasiou, Efstathios Bekris, Marios Marselos, Leigh Panlilio, Christa E Müller, Steven R Goldberg, Sergi Ferré.   

Abstract

RATIONALE: There is no consensus on the contribution of adenosine A(1) and A(2A) receptor blockade to motor-activating effects of caffeine.
OBJECTIVE: Our aim was to use a detailed and continuous observational method to compare the motor effects induced by caffeine with those induced by selective A(1) and A(2A) receptor antagonists.
METHODS: The behavioral repertoire induced by systemic administration of caffeine (3, 10, and 30 mg/kg), A(1) receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (CPT; 1.2, 4.8 and 7.2 mg/kg), and A(2A) receptor antagonist 3-(3-hydroxypropyl)-8-(m-methoxystyryl)-7-methyl-1-propargylxanthine phosphate disodium salt (MSX-3; 1, 3, and 10 mg/kg) was analyzed. The effects of pretreatment with the selective A(1) receptor agonist N (6)-cyclopentyladenosine (CPA; 0.1 mg/g) and the selective A(2A) receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxyamidoadenosine (CGS 21680; 0.2 mg/kg) on the pattern of motor activation induced by caffeine, CPT, or MSX-3 were also examined.
RESULTS: The pattern of behavioral activation induced by caffeine was better mimicked by CPT than by MSX-3. Coadministration of CPT and MSX-3 gave different results depending on the dose and the type of behavioral response. CPA was more effective at decreasing the activating effects of caffeine and CPT than those of CGS 21680. On the other hand, CGS 21680 was more effective at decreasing the activating effects of MSX-3 than those of caffeine or CPT. Factor analysis revealed a complex three-dimensional behavioral profile for caffeine that was similar to the profile for CPT and was different from the profile for MSX-3.
CONCLUSIONS: The results indicate a predominant role for A(1) receptors in the motor-activating effects of acutely administered caffeine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205915     DOI: 10.1007/s00213-005-0173-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.

Authors:  R Sauer; J Maurinsh; U Reith; F Fülle; K N Klotz; C E Müller
Journal:  J Med Chem       Date:  2000-02-10       Impact factor: 7.446

2.  Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist.

Authors:  L Halldner; G Lozza; K Lindström; B B Fredholm
Journal:  Eur J Pharmacol       Date:  2000-10-20       Impact factor: 4.432

3.  Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose.

Authors:  M Gasior; M Jaszyna; J Peters; S R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

4.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor.

Authors:  C Ledent; J M Vaugeois; S N Schiffmann; T Pedrazzini; M El Yacoubi; J J Vanderhaeghen; J Costentin; J K Heath; G Vassart; M Parmentier
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

5.  Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats.

Authors:  Marcello Solinas; Sergi Ferré; Katerina Antoniou; Davide Quarta; Zuzana Justinova; Jörg Hockemeyer; Lara A Pappas; Pavan N Segal; Carrie Wertheim; Christa E Müller; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

Review 6.  Caffeine--an atypical drug of dependence.

Authors:  J W Daly; B B Fredholm
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

7.  Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine.

Authors:  Maria Lindskog; Per Svenningsson; Laura Pozzi; Yong Kim; Allen A Fienberg; James A Bibb; Bertil B Fredholm; Angus C Nairn; Paul Greengard; Gilberto Fisone
Journal:  Nature       Date:  2002-08-15       Impact factor: 49.962

8.  Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens.

Authors:  Marcello Solinas; Sergi Ferré; Zhi-Bing You; Marzena Karcz-Kubicha; Patrizia Popoli; Steven R Goldberg
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

9.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding.

Authors:  J Baumgold; O Nikodijevic; K A Jacobson
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

View more
  25 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 3.  Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Authors:  Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2016-01-20       Impact factor: 4.530

4.  Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

Authors:  Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone
Journal:  Behav Brain Res       Date:  2006-12-21       Impact factor: 3.332

Review 5.  Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Authors:  S Ferré; I Diamond; S R Goldberg; L Yao; S M O Hourani; Z L Huang; Y Urade; I Kitchen
Journal:  Prog Neurobiol       Date:  2007-05-01       Impact factor: 11.685

6.  Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers.

Authors:  Francisco Ciruela; Vicent Casadó; Ricardo J Rodrigues; Rafael Luján; Javier Burgueño; Meritxell Canals; Janusz Borycz; Nelson Rebola; Steven R Goldberg; Josefa Mallol; Antonio Cortés; Enric I Canela; Juan F López-Giménez; Graeme Milligan; Carme Lluis; Rodrigo A Cunha; Sergi Ferré; Rafael Franco
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

7.  Paraxanthine: Connecting Caffeine to Nitric Oxide Neurotransmission.

Authors:  Sergi Ferré; Marco Orrú; Xavier Guitart
Journal:  J Caffeine Res       Date:  2013-06

Review 8.  Neuroadaptations in adenosine receptor signaling following long-term ethanol exposure and withdrawal.

Authors:  Tracy R Butler; Mark A Prendergast
Journal:  Alcohol Clin Exp Res       Date:  2011-07-18       Impact factor: 3.455

9.  Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice.

Authors:  Carina R Boeck; Caroline Martinello; Adalberto A de Castro; Morgana Moretti; Tiago Dos Santos Casagrande; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-19       Impact factor: 3.000

10.  A novel strategy for dissecting goal-directed action and arousal components of motivated behavior with a progressive hold-down task.

Authors:  Matthew R Bailey; Greg Jensen; Kathleen Taylor; Chris Mezias; Cait Williamson; Rae Silver; Eleanor H Simpson; Peter D Balsam
Journal:  Behav Neurosci       Date:  2015-06       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.